Literature DB >> 8026515

Immunoglobulin isotype regulation by antigen-presenting cells in vivo.

G De Becker1, T Sornasse, N Nabavi, H Bazin, F Tielemans, J Urbain, O Leo, M Moser.   

Abstract

The isotype and magnitude of the B cell response clearly depends on the in vivo activation of T helper (Th) cells which secrete different lymphokines. Since Th are activated by the presentation of the antigen on specialized cells, we wished to test whether the nature of the antigen-presenting cells (APC) influences the isotypic profile of the humoral response. Data are presented showing that antigen-pulsed dendritic cells (DC) and peritoneal macrophages induce the synthesis of specific antibodies when injected in syngeneic animals. By contrast, a single injection of antigen-pulsed resting B cells does not prime the mice in vivo. Moreover, the injection of antigen-pulsed DC induces the synthesis of specific IgG2a and IgG1 antibodies, whereas peritoneal macrophages favor the production of IgG1 and IgE antibodies specific for the antigen. These data show that the isotype and the amplitude of the B cell response can be regulated by the nature of the APC, and indirectly suggest that Th cell differentiation is controlled at the level of antigen presentation.

Entities:  

Mesh:

Year:  1994        PMID: 8026515     DOI: 10.1002/eji.1830240710

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

1.  Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice.

Authors:  J M Ball; M E Hardy; R L Atmar; M E Conner; M K Estes
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

2.  Effects of the route of infection on immunoglobulin G subclasses and specificity of the reovirus-specific humoral immune response.

Authors:  A S Major; C F Cuff
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

Review 3.  Microneedle and mucosal delivery of influenza vaccines.

Authors:  Sang-Moo Kang; Jae-Min Song; Yeu-Chun Kim
Journal:  Expert Rev Vaccines       Date:  2012-05       Impact factor: 5.217

Review 4.  Cutaneous immunization: an evolving paradigm in influenza vaccines.

Authors:  Harvinder S Gill; Sang-Moo Kang; Fu-Shi Quan; Richard W Compans
Journal:  Expert Opin Drug Deliv       Date:  2014-02-12       Impact factor: 6.648

5.  Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles.

Authors:  Yeu-Chun Kim; Fu-Shi Quan; Dae-Goon Yoo; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

6.  Murine dendritic cells pulsed in vitro with Toxoplasma gondii antigens induce protective immunity in vivo.

Authors:  I Bourguin; M Moser; D Buzoni-Gatel; F Tielemans; D Bout; J Urbain; O Leo
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

7.  Lead effects on development and function of bone marrow-derived dendritic cells promote Th2 immune responses.

Authors:  Donghong Gao; Tapan K Mondal; David A Lawrence
Journal:  Toxicol Appl Pharmacol       Date:  2007-04-12       Impact factor: 4.219

8.  Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch.

Authors:  Sungsil Moon; Yuhuan Wang; Chris Edens; Jon R Gentsch; Mark R Prausnitz; Baoming Jiang
Journal:  Vaccine       Date:  2012-11-19       Impact factor: 3.641

9.  Macrophages pulsed with Streptococcus pneumoniae elicit a T cell-dependent antibody response upon transfer into naive mice.

Authors:  Sam Vasilevsky; Jesus Colino; Roman Puliaev; David H Canaday; Clifford M Snapper
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

10.  Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin.

Authors:  Fu-Shi Quan; Yeu-Chun Kim; Dae-Goon Yoo; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.